| 查看: 432 | 回复: 0 | ||
西点6688木虫 (正式写手)
|
[求助]
各位大神，求助一段话的翻译，谢谢！~荟萃分析
|
|
RESULT We summarized 20 trials carried out in metastatic melanoma (MM), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) patients receiving anti-PD-1/PD-L1 antibodies (4230 MM, 1417 NSCLC and 312 RCC patients). Positive PD-L1 MM patients showed a significant decrease (53%) in the risk of mortality vs. negative cases with no heterogeneity. Furthermore, SORRs were 45% and 27% in PD-L1 positive and negative patients, respectively, and SOR indicates a significant difference in term of responses: 2.14 (95% CI: 1.65, 2.77), with low between-study heterogeneity (I2= 35%). Furthermore, results from randomized clinical trials on MM showed that PD-L1 expression is significantly associated with greater clinical response rates to anti-PD1 treatments (SOR 1.89; 95%CI: 1.35, 2.64) but not to other treatments (SOR 0.96; 95%CI: 0.5, 1.87). 因为是荟萃学分析，有些术语不理解，望专业人士点播，谢谢！原文网址： https://www.ncbi.nlm.nih.gov/pubmed/26895815 |
回复此楼» 猜你喜欢
今年E04面上
已经有18人回复
-
2026年面上项目中了，2A+B, 会评顺利通过
已经有10人回复
-
大龄残疾硕士的一点执念
已经有16人回复
-
刑法学论文投稿求助
已经有5人回复
-
Journal of Environmental Chemical Engineering
已经有3人回复
-
最后一年，祈求好运
已经有3人回复
-
风电环氧领域
已经有3人回复
-
售T0P一区SCI文章，我:8O5.51.O.54,科目齐全,可＋急
已经有4人回复
-
植酸TLC薄层色谱爬板
已经有6人回复
